Free Trial

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.17 Consensus Price Target from Analysts

Oric Pharmaceuticals logo with Medical background

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has received a consensus rating of "Buy" from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $18.57.

A number of brokerages have weighed in on ORIC. LADENBURG THALM/SH SH began coverage on Oric Pharmaceuticals in a report on Tuesday. They issued a "buy" rating and a $15.00 target price for the company. Wedbush reiterated an "outperform" rating and issued a $20.00 target price on shares of Oric Pharmaceuticals in a report on Monday, June 23rd. Oppenheimer lowered their target price on Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and issued a $21.00 target price on shares of Oric Pharmaceuticals in a report on Monday, May 5th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Oric Pharmaceuticals in a report on Tuesday, May 6th.

Check Out Our Latest Stock Report on ORIC

Oric Pharmaceuticals Price Performance

Shares of Oric Pharmaceuticals stock traded up $0.47 during midday trading on Friday, reaching $10.90. The company had a trading volume of 856,396 shares, compared to its average volume of 789,769. The stock has a fifty day moving average price of $8.01 and a 200 day moving average price of $7.84. The firm has a market cap of $928.90 million, a PE ratio of -5.83 and a beta of 1.54. Oric Pharmaceuticals has a fifty-two week low of $3.90 and a fifty-two week high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. As a group, sell-side analysts forecast that Oric Pharmaceuticals will post -2.17 EPS for the current year.

Insider Buying and Selling

In other news, CFO Dominic Piscitelli sold 32,466 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total transaction of $340,893.00. Following the transaction, the chief financial officer directly owned 68,317 shares of the company's stock, valued at $717,328.50. This represents a 32.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Angie You bought 26,597 shares of the stock in a transaction dated Friday, June 20th. The shares were purchased at an average cost of $9.39 per share, for a total transaction of $249,745.83. Following the completion of the transaction, the director directly owned 26,597 shares of the company's stock, valued at $249,745.83. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 40,000 shares of company stock worth $416,289 over the last ninety days. 6.82% of the stock is owned by insiders.

Hedge Funds Weigh In On Oric Pharmaceuticals

A number of institutional investors have recently modified their holdings of ORIC. Invesco Ltd. raised its position in Oric Pharmaceuticals by 8.5% in the 4th quarter. Invesco Ltd. now owns 23,958 shares of the company's stock valued at $193,000 after buying an additional 1,876 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Oric Pharmaceuticals by 22.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after buying an additional 2,520 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Oric Pharmaceuticals by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock valued at $226,000 after buying an additional 3,131 shares during the last quarter. Swiss National Bank raised its position in Oric Pharmaceuticals by 5.4% in the 4th quarter. Swiss National Bank now owns 62,400 shares of the company's stock valued at $504,000 after buying an additional 3,200 shares during the last quarter. Finally, American Century Companies Inc. raised its position in Oric Pharmaceuticals by 4.4% in the 1st quarter. American Century Companies Inc. now owns 112,628 shares of the company's stock valued at $628,000 after buying an additional 4,766 shares during the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.

About Oric Pharmaceuticals

(Get Free Report

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

Recommended Stories

Analyst Recommendations for Oric Pharmaceuticals (NASDAQ:ORIC)

Should You Invest $1,000 in Oric Pharmaceuticals Right Now?

Before you consider Oric Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.

While Oric Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines